Dr. Elliott Block

• 
  www.sec.gov/Archives/edgar/data/924921/0001116502-01-50 - [Cached Version]
  Published on: 4/4/2001    Last Visited: 9/14/2001  

  Elliott Block , Ph.D..
  ...
  ELLIOTT BLOCK , Ph.D. , 56 , President since September 12 , 2000 and Chief Executive Officer since May 1999 and a Director of TCPI INC since September 1999 , has responsibility for TCPI INC's strategic direction and day-to-day business operations.Dr. Block has more than 28 years of senior level experience in the research , manufacturing and international marketing of over-the-counter and clinical diagnostic products , as well as the operation of licensed clinical laboratories.Dr. Block was the President , CEO and a director of Medicorp Inc. , a privately held biomedical company headquartered in Montreal , Canada from its inception in 1986 to 1999.Medicorp is involved in the research , manufacturing and international marketing of clinical diagnostic tests , the distribution of research kits and reagents in Canada and the operation of a licensed clinical laboratory.He was also instrumental in forming Decision Diagnostics LLC , a joint venture with Dianon Systems , Inc. , to license new technology for the improved diagnosis of prostate cancer.From 1981 through 1985 , Dr. Block served as a director and the first President and CEO of Hygeia Sciences , Inc..Hygeia developed and manufactured the First Response over-the-counter pregnancy and ovulation kits marketed by Tambrands , Inc. , which subsequently purchased Hygeia.These same assays were manufactured for Hoffmann-La Roche , which sold them to the professional market.From 1972 through 1981 , he held positions of increasing responsibility at Becton Dickinson Immunodiagnostics , a division of Becton , Dickinson & Co. , including Vice President , Operations and Vice President , Research & Development.Previously , he worked in clinical diagnostics research at Syva Company.Dr. Block has a Ph.D. from Brandeis University and was an Alexander von Humboldt Fellow at the University of Cologne , Germany.He has a B.A. degree from Queens College.

• 
  3rd Qtr 2001 - [Cached Version]
  Published on: 9/5/2001    Last Visited: 11/12/2003  

  Elliott Block, Ph.D., President & Chief Executive Officer, commented, "This was a difficult, but absolutely necessary, decision for TCPI to make.

• 
  At-Home Medical Test Kits Increase in Popularity... - [Cached Version]
  Published on: 8/25/2001    Last Visited: 6/9/2002  

  TCPI's president, Elliott Block, believes at-home testing will gain huge popularity in coming years.
  
  "Home diagnostic testing is in its early stages," he said."Many of the products introduced over the past few years are gaining in consumer acceptance.I'd say the market is similar to where home pregnancy testing was 10 to 15 years ago."
  
  TCPI launched its HealthCheck home-testing products in 1997.They are available in 17,000 drugstores in the United States and Canada, as well as online.

• 
  Business topics - [Cached Version]
  Published on: 1/19/2000    Last Visited: 9/20/2000  

  TCPI Inc. of Pompano Beach, which manufactures medical diagnostic products, said the board of directors elected Martin Gurkin as chairman of the board and appointed TCPI's chief executive officer, Elliott Block, to also become president.

• 
  Daily news reports on Nasdaq over-the-counter bulletin... - [Cached Version]
  Published on: 12/14/2000    Last Visited: 4/2/2001  

  We are extremely pleased with the court's decision in this matter , said Elliott Block , Ph.D. , President and Chief Executive Officer of TCPI , Inc.TCPI , Inc. markets point-of-care medical diagnostic products for use at home , in physician offices , and other healthcare locations and distributes them worldwide through multiple channels under its own HealthCheck ( R ) brand as well as OEM ( original equipment manufacture ) and private label programs.The Company also markets its patented SR-38 ( TM ) skin permeation enhancer and owns a patent-protected , proprietary portfolio of transdermal and dermal drug delivery technologies.TCPI presently holds 26 U.S. and foreign patents , and has 61 domestic and foreign patent applications pending.TCPI closed the day unchanged on light volume of 277 , 100 shares.Average daily volume is 1 , 200 , 000 shares.
  
  ...
  We are extremely pleased with the court's decision in this matter , said Elliott Block , Ph.D. , President and Chief Executive Officer of TCPI , Inc.TCPI , Inc. markets point-of-care medical diagnostic products for use at home , in physician offices , and other healthcare locations and distributes them worldwide through multiple channels under its own HealthCheck ( R ) brand as well as OEM ( original equipment manufacture ) and private label programs.The Company also markets its patented SR-38 ( TM ) skin permeation enhancer and owns a patent-protected , proprietary portfolio of transdermal and dermal drug delivery technologies.TCPI presently holds 26 U.S. and foreign patents , and has 61 domestic and foreign patent applications pending.TCPI closed the day unchanged on light volume of 277 , 100 shares.Average daily volume is 1 , 200 , 000 shares.

• 
  Esurg.com News - [Cached Version]
  Published on: 8/17/2000    Last Visited: 9/15/2000  

  TCPI's president, Elliott Block, believes at-home testing will gain huge popularity in coming years.
  
  Home diagnostic testing is in its early stages, he said.Many of the products introduced over the past few years are gaining in consumer acceptance.i would say the market is similar to where home pregnancy testing was 10 to 15 years ago..
  
  TCPI launched its HealthCheck home-testing products in 1997.They are available in 17, 000 drugstores in the United States and Canada, as well as online.

• 
  Group 50® ~ Consultants Resume - [Cached Version]
  Published on: 7/29/2007    Last Visited: 5/1/2008  

  Elliott Block
  ...
  Elliott has experience in negotiating mutually rewarding, successful agreements for technology transfer and marketing and distribution in the US and internationally on behalf of large [acquirer] and small [seller] companies.He has a track record in motivating personnel and coordinating diverse resources to generate growth in technology-based companies.His strengths are evaluation, planning & direction of complex projects, including integration/motivation of all departments.
  ...
  Elliott developed and implemented a new business and marketing plan leading to increased sales and profits, ultimately leading to successful sale of the business as the exit strategy.
  ...
  Elliott turned around an acquired company from loss to profitable in 2 years by international expansion and diversification of the Company's product lines to emphasize expanding research reagents business.He acquired an AIDS treatment from Cambridge University, had it patented and taken through Phase I/II clinical trials and sublicensed to HemaCare Corporation.He formed and managed a joint venture with Dianon Systems [now part of LabCorp] to license a patented prostate cancer diagnostic technology worldwide.He negotiated with LabOne, Inc. [now part of Quest Diagnostics] of Kansas City to form in Montréal a clinical laboratory joint venture of which he was President and Director.He was instrumental in implementing a company-wide GMP program and obtaining company-wide ISO 9001 certification.HYGEIA SCIENCES, INC.Newton, MA 1981 - 1986
  ...
  Elliott was responsible for R&D activities in New York and California facilities where he directed 38 employees and a $2.5 million annual budget.He developed a broad product line of innovative assays resulting in a doubling of sales while decreasing R&D costs from 20% to 11% of sales.

• 
  Headlines/Breaking News from South Florida Business... - [Cached Version]
  Published on: 10/25/2005    Last Visited: 10/25/2005  

  Technical Chemicals & Products (Nasdaq: TCPI), a Pompano Beach-based manufacturer of medical diagnostic products, says its CEO, Elliott Block, Ph.D., has been appointed to the company's board.He replaces Kathryn Harrigan, who resigned due to increased academic responsibilities at Columbia University's Graduate School of Business.Block, 54, has been CEO since May.Previously, he was president, CEO and a director of Medicorp Inc., a privately held biomedical company with headquarters in Montreal, Canada.

• 
  HomeCare Monday - [Cached Version]
  Published on: 2/12/2001    Last Visited: 12/7/2001  

  "The termination of these lawsuits is a significant event for us and brings closure to legal matters that have been going on over the past three years," TCPI president and chief executive officer Elliott Block said."Ongoing development of our current noninvasive glucose monitoring technology can proceed without concern of future lawsuits from the Americare companies."
  
  ResMed Earnings Rise in Q2POWAY, Calif.--ResMed reported net earnings of $6.9 million, or 21 cents a share, for the fiscal 2001 second quarter ended Dec. 31, a 29 percent increase compared with net earnings of $5.4 million, or 17 cents a share, for the same quarter last year.
  
  For the six-month period, the company posted net earnings of $13.5 million, or 41 cents a share, a 32 percent increase compared with net earnings of $10.2 million, or 32 cents a share, a year ago.

• 
  Medbizpeople.com - Job Center - [Cached Version]
  Published on: 5/15/2001    Last Visited: 7/10/2001  

  Nevertheless , the combination of the meter and membrane patch comprising the System produced results that require further improvements , said Elliott Block , Ph.D. , President of TCPI , Inc..TCPI does not have sufficient financial resources to continue development of this project.Thus , further activity would be conducted only when sufficient funding is available , continued Dr. Block.About the TD Glucose Monitoring System.
  
  The TD Glucose Monitoring System is intended to be a painless , bloodless and easy-to-use method for diabetics to monitor their glucose levels without the discomfort and inconvenience associated with fingerstick blood glucose monitoring systems.This system incorporates a small skin patch and electronic meter to monitor glucose levels.After the patch has been placed on the forearm for five minutes , a small electronic meter is held up to the patch and produces a glucose reading.The single-use patch is then removed and disposed.
  
  The TD Glucose Monitoring System combines proprietary , patent-pending transdermal technology with membrane-based diagnostic technology.

Page:  1 2